Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | APP | P05067 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | AGXT | P21549 | 2/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27028506 | 0.89 | NPC1 (0.44) | NPC1RAB9AAPPMAOBABCB1 | |
| SCHEMBL23115605 | 0.84 | BRD4 (0.49) | SMN1; SMN2GAA | |
| SCHEMBL20156059 | 0.76 | SMN1; SMN2 (0.44) | NPC1RAB9AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL23115668 | 0.74 | GAA (0.49) | NPC1RAB9AAPPMAOBIDO1 | |
| SCHEMBL26690290 | 0.72 | BRD4 (0.47) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19170474 | 0.72 | MEN1 (0.52) | NPC1RAB9AALDH1A1SMN1; SMN2CYP19A1 | |
| SCHEMBL26690025 | 0.70 | BRD4 (0.45) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL31465373 | 0.70 | NPC1 (0.45) | NPC1RAB9AAPPMAOBABCB1 | |
| SCHEMBL12301192 | 0.70 | NPC1 (0.70) | NPC1RAB9AAPPMAOBABCB1 | |
| SCHEMBL26690067 | 0.70 | BRD4 (0.47) | ALDH1A1ABCB1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12297190-B2 | Modulators of STING (stimulator of interferon genes) | PFIZER INC. (US) | 2025-05-13 | — | — | US | disclosed |
| EP-4526298-A1 | PYRAZOLE DERIVATIVES AS STING AGONISTS | F. Hoffmann-La Roche AG (CH) | 2025-03-26 | — | — | EP | disclosed |
| US-20250074913-A1 | PYRAZOLE DERIVATIVES AS STING AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-06 | — | — | US | disclosed |
| CN-119212989-A | Pyrazole derivatives as STING agonists | 豪夫迈·罗氏有限公司 | 2024-12-27 | — | — | CN | disclosed |
| US-20240383903-A1 | Modulators of STING (Stimulator of Interferon Genes) | PFIZER INC. (US) | 2024-11-21 | — | — | US | disclosed |
| US-11964978-B2 | Modulators of STING (stimulator of interferon genes) | PFIZER INC. (US) | 2024-04-23 | — | — | US | disclosed |
| EP-4308563-A1 | MODULATORS OF STING (STIMULATOR OF INTERFERON GENES) | Pfizer Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-117321055-A | Modulators of STING (interferon gene stimulators) | 辉瑞公司 | 2023-12-29 | — | — | CN | disclosed |
| WO-2023222644-A1 | PYRAZOLE DERIVATIVES AS STING AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023222644-A1 | PYRAZOLE DERIVATIVES AS STING AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| US-20220306641-A1 | Modulators of STING (Stimulator of Interferon Genes) | PFIZER INC. (US) | 2022-09-29 | — | — | US | disclosed |
| WO-2022195462-A1 | MODULATORS OF STING (STIMULATOR OF INTERFERON GENES) | PFIZER INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| EP-4034534-A1 | POLYHETEROCYCLIC MODULATORS OF STING (STIMULATOR OF INTERFERON GENES) | Pfizer Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| CN-114728946-A | Polyheterocyclic modulators of STING (stimulator of interferon genes) | 辉瑞公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2021059136-A1 | POLYHETEROCYCLIC MODULATORS OF STING (STIMULATOR OF INTERFERON GENES) | PFIZER INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| WO-2021059136-A1 | POLYHETEROCYCLIC MODULATORS OF STING (STIMULATOR OF INTERFERON GENES) | PFIZER INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| US-20210087180-A1 | Modulators of STING (Stimulator of Interferon Genes) | PFIZER INC. (US) | 2021-03-25 | — | — | US | disclosed |
| US-20210087180-A1 | Modulators of STING (Stimulator of Interferon Genes) | PFIZER INC. (US) | 2021-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12297190-B2 | Modulators of STING (stimulator of interferon genes) | STING1, IRF3, CGAS | NPC1 2332/4885RAB9A 1607/4885APP 3427/4885 |
| US-20250074913-A1 | PYRAZOLE DERIVATIVES AS STING AGONISTS | STING1, CGAS, MAVS | NPC1 1915/4885RAB9A 413/4885APP 1595/4885 |
| US-11964978-B2 | Modulators of STING (stimulator of interferon genes) | STING1, IRF3, CGAS | NPC1 2796/4885RAB9A 1879/4885APP 2909/4885 |
| US-20220306641-A1 | Modulators of STING (Stimulator of Interferon Genes) | STING1, IRF3, CGAS | NPC1 2796/4885RAB9A 1879/4885APP 2909/4885 |
| US-20240383903-A1 | Modulators of STING (Stimulator of Interferon Genes) | STING1, IRF3, CGAS | NPC1 2796/4885RAB9A 1879/4885APP 2909/4885 |
| US-20210087180-A1 | Modulators of STING (Stimulator of Interferon Genes) | STING1, IRF3, CGAS | NPC1 2332/4885RAB9A 1607/4885APP 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.